Cisplatin adds to, does not synergize with, radiation lymphocyte apoptosis
This translational study clarifies the temporal window and additive nature of hematologic injury from concurrent cisplatin-radiotherapy, informing how pharmacists conceptualize myelosuppression risk during chemoradiation.
Cisplatin adds to radiation's apoptotic impact on cancer patients' lymphocytes.
Understanding the apoptotic effects of cisplatin with radiation enhances the safety and efficacy of cancer treatments. Cisplatin and radiation have an additive effect on lymphocyte apoptosis, peaking three days post-treatment. The study establishes a critical timeframe for hematologic damage, aiding in treatment schedule optimization. Cisplatin and radiation together increase lymphocyte apoptosis in a time-dependent, additive manner.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Sak A, Mladenov E, Alberti Y, et al. Cisplatin enhances radiation-induced apoptosis in peripheral lymphocytes of cancer patients: in vivo and in vitro findings. Radiation oncology (London, England). 2026;21(1). doi:10.1186/s13014-026-02921-x
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.